Facebook Pixel Code

Dr Reddy’s launches Remdesivir for COVID-19 treatment in India

According to a press release from the drug maker, the launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Dr Reddy Laboratories Ltd, Redyx in india, Remdesivir, COVID 19 patients,COVID-19 in India, covid 19 drugs, latest news on coronavirus outbreak
Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms.

Dr Reddys Laboratories Ltd on Wednesday announced the launch of Remdesivir, meant for treatment of COVID-19 patients, under a brand name ‘Redyx’ in India.

According to a press release from the drug maker, the launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms.

“Dr Reddy’s Redyx is available in strength of 100 mg vial,” it said.

Chief Executive Officer of Branded Markets (India and Emerging Markets), Dr Reddys Laboratories, M V Ramana said, “We will continue our efforts to develop products that address significant unmet needs of patients.

The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”

Get live Share Market updates, Stock Market Quotes, and the latest India News and business news on Financial Express. Download the Financial Express App for the latest finance news.

First published on: 09-09-2020 at 13:03 IST
Market Data
Market Data
Today’s Most Popular Stories ×